Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S John Weroha

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|April 26, 2011
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinomaS John Weroha, Ann L Oberg, Katie L Allen Ziegler, et al.
Gynecologic Oncology|July 13, 2023
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Anousheh Shafa, A Brooke Watkins, Michaela E McGree, et al.
Gynecologic Oncology|May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.
Gynecologic Oncology|October 16, 2022
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancerSimone Garzon, Tommaso Grassi, Andrea Mariani, et al.
The American Journal of Hospice & Palliative Care|May 5, 2018
Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With CancerDavid J Bartlett, Daniel S Childs, Carmen Radecki Breitkopf, et al.
BJC Reports|January 14, 2025
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumorsAurora Norman, Mahesh Seetharam, Jacob Allred, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 4, 2018
Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian CarcinomaBrooke L Fridley, Junqiang Dai, Rama Raghavan, et al.
Journal of Gynecologic Oncology|June 23, 2024
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX modelsManisha Taya, Xiaonan Hou, Jennifer T Veneris, et al.
Translational Oncology|April 26, 2022
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumorsMax J Cotler, Khalil B Ramadi, Xiaonan Hou, et al.
Gynecologic Oncology|June 2, 2026
Clinical relevance of transcriptome profiling for assessing prognosis, platinum insensitivity, and precision therapeutics in endometrial cancerJesus Gonzalez-Bosquet, Maryam Shahi, Siddhartha Yadav, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|April 26, 2011
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinomaS John Weroha, Ann L Oberg, Katie L Allen Ziegler, et al.
Gynecologic Oncology|July 13, 2023
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Anousheh Shafa, A Brooke Watkins, Michaela E McGree, et al.
Gynecologic Oncology|May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.
Gynecologic Oncology|October 16, 2022
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancerSimone Garzon, Tommaso Grassi, Andrea Mariani, et al.
The American Journal of Hospice & Palliative Care|May 5, 2018
Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With CancerDavid J Bartlett, Daniel S Childs, Carmen Radecki Breitkopf, et al.
BJC Reports|January 14, 2025
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumorsAurora Norman, Mahesh Seetharam, Jacob Allred, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 4, 2018
Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian CarcinomaBrooke L Fridley, Junqiang Dai, Rama Raghavan, et al.
Journal of Gynecologic Oncology|June 23, 2024
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX modelsManisha Taya, Xiaonan Hou, Jennifer T Veneris, et al.
Translational Oncology|April 26, 2022
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumorsMax J Cotler, Khalil B Ramadi, Xiaonan Hou, et al.
Gynecologic Oncology|June 2, 2026
Clinical relevance of transcriptome profiling for assessing prognosis, platinum insensitivity, and precision therapeutics in endometrial cancerJesus Gonzalez-Bosquet, Maryam Shahi, Siddhartha Yadav, et al.
Pageof 9